Page 1 of 3

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Proposed Single Technology Appraisal (STA)**

# Telbivudine for the treatment of chronic hepatitis B

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors  Novartis Pharmaceuticals UK Ltd (telbivudine)  Patient/carer groups  AVERT British Liver Trust Mainliners Medical Foundation for AIDS & Sexual Health National AIDS Trust Network of Self-help HIV and Aids groups Specialised Healthcare Alliance Terence Higgins Trust UK Coalition of People Living with HIV and AIDS  Professional groups British Association for Sexual Health and HIV British Association for the Study of the Liver British Infection Society British Liver Nurses Forum British Society of Gastroenterology Community Practitioners' & Health Visitors Association	<ul> <li>General</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>National Public Health Service for Wales</li> <li>NHS Confederation</li> <li>NHS Purchasing and Supply Agency</li> <li>NHS Quality Improvement Scotland</li> <li>Scottish Medicines Consortium</li> <li>Possible comparator manufacturer(s)</li> <li>Gilead Sciences (adefovir dipivoxil)</li> <li>GlaxoSmithKline (lamivudine)</li> <li>Roche Products Limited (interferon alfa 2a, peginterferon alfa 2a)</li> <li>Schering-Plough Ltd (interferon alfa 2a, interferon alfa 2b)</li> <li>Bristol-Myers Squibb Pharmaceuticals Ltd (entecavir)</li> <li>Relevant research groups</li> <li>Foundation for Liver Research</li> </ul>
<ul> <li>and AIDS</li> <li>Professional groups</li> <li>British Association for Sexual Health and HIV</li> <li>British Association for the Study of the Liver</li> <li>British Infection Society</li> <li>British Liver Nurses Forum</li> <li>British Society of Gastroenterology</li> <li>Community Practitioners' &amp; Health</li> </ul>	<ul> <li>Gilead Sciences (adefovir dipivoxil)</li> <li>GlaxoSmithKline (lamivudine)</li> <li>Roche Products Limited (interferon alfa 2a, peginterferon alfa 2a)</li> <li>Schering-Plough Ltd (interferon alfa 2a, interferon alfa 2b)</li> <li>Bristol-Myers Squibb Pharmaceuticals Ltd (entecavir)</li> <li>Relevant research groups</li> <li>Foundation for Liver Research</li> </ul>
<ul> <li>Visitors Association</li> <li>Hepatitis Nurse Specialist Forum</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians of Edinburgh</li> <li>Royal Pharmaceutical Society</li> </ul>	<ul> <li>MRC Clinical Trials Unit</li> <li>Evidence Review Group</li> <li>Assessment group tbc</li> <li>National Coordinating Centre for Health Technology Assessment</li> </ul>

National Institute for Health and Clinical Excellence

Consultation on the provisional matrix for the proposed appraisal of telbivudine for the treatment of chronic hepatitis B

Issue date: December 2006

Consultees	Commentators (no right to submit or appeal)
<ul><li>Society for General Microbiology</li><li>UK Clinical Virology Network</li></ul>	
Others      Bury PCT     Department of Health     South Worcestershire PCT     Welsh Assembly Government	

#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

### Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Consultation on the provisional matrix for the proposed appraisal of telbivudine for the treatment of chronic hepatitis B

Issue date: December 2006 Page 3 of 3

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.